Valeant Pharmaceuticals Intl Inc (VRX) reported quarterly earnings results on Tuesday, Jun-7-2016. The company reported $1.27 earnings per share for the quarter, missing the analyst consensus estimate by $-0.10. Analysts had a consensus of $1.37. The company posted revenue of $2371.60 million in the period, compared to analysts expectations of $2337.60 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Shares were Reiterated by Rodman & Renshaw on May 3, 2016 to “Buy” and Lowered the Price Target to $ 102 from a previous price target of $105 .Shares were Reiterated by RBC Capital Mkts on Apr 12, 2016 to “Sector Perform” and Lowered the Price Target to $ 65 from a previous price target of $69 .Shares were Reiterated by Rodman & Renshaw on Apr 11, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $118 .
Valeant Pharmaceuticals Intl Inc closed down -0.54 points or -1.84% at $28.87 with 1,91,69,376 shares getting traded on Friday. Post opening the session at $29.41, the shares hit an intraday low of $28.57 and an intraday high of $29.71 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Nov 9, 2015, J. Michael Pearson (Chief Executive Officer) sold 1,297,399 shares at $78.53 per share price. According to the SEC, on Oct 22, 2015, Ronald Harold Farmer (director) purchased 1,500 shares at $175.90 per share price. On Aug 3, 2015, Robert L. Rosiello (CFO) purchased 7,875 shares at $255.62 per share price, according to the Form-4 filing with the securities and exchange commission.
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.